Breast cancer genetics. Implications of clinical practice

Hematol Oncol Clin North Am. 2000 Jun;14(3):705-25. doi: 10.1016/s0889-8588(05)70304-x.
No abstract available

Publication types

  • Review

MeSH terms

  • Age of Onset
  • Anticarcinogenic Agents / therapeutic use
  • BRCA1 Protein / physiology
  • BRCA2 Protein
  • Breast Neoplasms / epidemiology
  • Breast Neoplasms / genetics*
  • Breast Neoplasms / prevention & control
  • Breast Neoplasms / psychology
  • Breast Neoplasms, Male / epidemiology
  • Breast Neoplasms, Male / genetics
  • Carcinoma / epidemiology
  • Carcinoma / genetics*
  • Carcinoma / prevention & control
  • Carcinoma / psychology
  • Case Management
  • Cyclin D1 / genetics
  • Cyclin D1 / physiology
  • DNA Mutational Analysis
  • Estrogen Antagonists / therapeutic use
  • Female
  • Gene Frequency
  • Genes, BRCA1
  • Genes, erbB-2
  • Genetic Counseling / psychology
  • Genetic Testing / psychology
  • Humans
  • Male
  • Mammography
  • Mastectomy
  • Neoplasm Proteins / genetics
  • Neoplasm Proteins / physiology
  • Neoplasms, Multiple Primary / genetics
  • Neoplastic Syndromes, Hereditary / epidemiology
  • Neoplastic Syndromes, Hereditary / genetics*
  • Oncogenes*
  • Ovarian Neoplasms / genetics
  • Ovariectomy
  • Phenotype
  • Raloxifene Hydrochloride / therapeutic use
  • Retrospective Studies
  • Risk
  • Tamoxifen / therapeutic use
  • Transcription Factors / genetics
  • Transcription Factors / physiology

Substances

  • Anticarcinogenic Agents
  • BRCA1 Protein
  • BRCA2 Protein
  • Estrogen Antagonists
  • Neoplasm Proteins
  • Transcription Factors
  • Tamoxifen
  • Cyclin D1
  • Raloxifene Hydrochloride